Scripta Medica, Volume 51, 2020: a Short Overview

  • Miloš P Stojiljković Faculty of Medicine, University of Banja Luka, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina
DOI: https://doi.org/10.5937/scriptamed51-30059
Keywords: Scripta Medica, Biomedical journal, Editorial process, Research articles

Abstract


This editorial presents the analysis of volumes 50 (2019) and 51 (2020) of Scripta Medica. Original articles made 53 % of 80 articles published in these two volumes. Article rejection rate was 38 %. Mean duration of period until reaching the first decision on an article was 20 days, while mean time until reaching the final decision was 31 days. Mean time needed for accepting the revised manuscript was 3 days, reflecting a significant decrease from 5 days in 2019 to 2 days in 2020. Mean time needed for reaching a decision to reject an article was 7 days. Coverage of the journal included both basic and clinical research and a considerable space was devoted to articles on COVID-19. Further efforts will be made in order to reach a more international recognition of the journal.

Author Biography

Miloš P Stojiljković, Faculty of Medicine, University of Banja Luka, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina

 Full Professor, Scientific field: Pharmacology, Toxicology and Clinical Pharmacology, Editor-in-Chief, Scripta Medica

References

Stojiljković MP. On the occasion of the fiftieth volume of the Scripta Medica (Banja Luka). Scr Med 2019;50(4):145-7.

Mijović B. COVID-19 – Lessons Learned. Scr Med 2020;51(1):1-5.

Igić R. Pharmacologist's view of the new Corona virus. Scr Med 2020;51(1):6-8.

Stojiljković MP. COVID-19 Pandemic, passing of Professor Folke Sjöqvist and other topics. Scr Med 2020;51(2):67-8.

Bhandari S, Sharma R, Singh Shaktawat A, Banerjee S, Patel B, Tak A, et al. COVID-19 related mortality profile at a tertiary care centre: a descriptive study. Scr Med 2020;51(2):69-73.

Aćimović J, Jandrić Lj, Đaković Dević J, Bojanić J, Subotić B, Radojčić T, et al. Epidemiological characteristics of COVID-19 infection in the Republic of Srpska: a hundred days survey. Scr Med 2020;51(2):74-80.

Janković S. Current status and future perspective of coronavirus disease 2019: a review. Scr Med 2020;51(2):101-9.

Stajić M, Maksimović ŽM, Verhaz A. COVID-19 pneumonia: when negative PCR testing does not rule out the disease. Scr Med 2020;51(2):120-3.

Janković SM. Antiviral therapy of COVID-19. Scr Med 2020;51(3):131-3.

Bhandari S, Shaktawat AS, Tak A, Shukla J, Gupta J, Patel B, et al. Relationship between ABO blood group phenotypes and nCOVID-19 susceptibility – a retrospective observational study. Scr Med 2020;51(4):217-22.

Published
2020/12/29
Issue
Vol. 51 No. 4 (2020): Q4
Section
Editorial
Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).